HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Lockwood, A. H. Search for Related Content PubMed PubMed Citation Articles by Lockwood, A. H.

Absorbed Doses of Radiation After An Intravenous Injection of N-13 Ammonia in Man: Concise Communication

University of Miami School of Medicine, Miami
Mount Sinai Medical Center, Miami Beach, Florida

Correspondence: For reprints contact: Alan H. Lockwood, MD, Dept. of Neurology D4-5, Univ. of Miami School of Medicine, P.O. Box 016960, Miami, FL 33101.

ABSTRACT

Using body distribution data with the MIRD tables and equations, the radiation dose delivered by an i.v. injection of N-13 ammonia has been calculated for several human organs. The liver and the urinary bladder wall receive 0.017 and 0.051 rad/mCi injected respectively; the latter can be reduced by early post-injection voiding. The brain-to-brain absorbed dose is 0.016 rad/mCi injected. The absorbed doses for the whole body, the red marrow, the ovaries, and the testes are, respectively, 0.0055, 0.0054, 0.0098, and 0.0010 rad/mCi injected. Severe liver disease is associated with a reduction in the fraction of the injected N-13 that is excreted in the urine, and thus causes a reduction in the absorbed dose to the urinary bladder wall from the bladder contents. Hepatomegaly increases the fraction of the N-13 ammonia trapped by the liver, and complicates calculation of the absorbed dose of radiation. These data should facilitate the evaluation of the risk from radiation absorption following i.v. injections of N-13 ammonia in humans.